DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Small EJ, Saad F, Chowdhury S. et al.
Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).
J Clin Oncol 2019;
37: 144-144
DOI: 10.1200/JCO.2019.37.7_suppl.144.
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.